Imagine bidding up a $9M market cap company by over forty percent just because the FDA approved the spelling of their proposed drug name.
That is Quoin Pharmaceuticals ($QNRX), ripping on conditional approval for the brand name "QYLEKI." Not regulatory approval for the drug itself—just the marketing label.
History has zero respect for name-drop rallies. Out of 27 historical gap-up days for $QNRX, the stock has faded to red 70% of the time, delivering a median intraday return of negative 7.58%.
Are you buying a clinical pipeline, or are you just funding the underwriters' summer vacation?